UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
DR. REDDY'S LABORATORIES, LTD. AND DR. REDDY'S LABORATORIES, INC., Petitioners,
v.
MONOSOL RX, LLC, Patent Owner.
Case No. IPR2016-XXXXX

DECLARATION OF RUSSELL J. MUMPER, Ph.D. IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 8,017,150

"POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM"



TABLE OF CONTENTS


		<u>I</u>	<u>Page</u>			
I.	QUALIFICATIONS AND BACKGROUND1					
	A.	Education and Experience; Prior Testimony				
	B.	Basis for Opinion and Materials Considered				
	C.	Scope of Work	9			
II.	SUM	IMARY OF OPINIONS10				
III.	LEG	AL STANDARDS14				
IV.	PER	SON OF ORDINARY SKILL IN THE ART16				
V.	THE '150 PATENT					
	A.	Relevant Prosecution History of the '150 Patent	20			
	B.	Priority Date of The '150 Patent				
VI.	BACKGROUND AND TECHNOLOGY TUTORIAL26					
	A.	Mucosally-Adhesive Drug Delivery Systems26				
	B.	Polymers30				
	C.	Molecular Weight of Polymers				
	D. Oral Films as Delivery Systems					
		1. Common Components of Oral Films	36			
		2. Determining the Ratios of Polymer Film Components	38			
VII.	SCOPE AND CONTENT OF THE PRIOR ART REFERENCES42					
	A. Scope and Content Of The Prior Art As Of October 12, 2001					
		1. WO2000/42992 ("Chen") (Ex. 1021)	43			
		2. U.S. Application Pub. No. 2002/0147201 ("Chen II")				



			(Ex. 1049)	47	
		3.	U.S. Patent No. 4,713,243 ("Schiraldi") (Ex. 1004)	48	
		4.	U.S. Patent No. 6,322,811 ("Verma") (Ex. 1005)	50	
		5.	U.S. Patent No. 5,656,296 ("Khan")	51	
	B.	Sumr	mary of the Scope and Content of the Prior Art	51	
		1.	Mucosally-adhesive water-soluble film products	51	
		2.	PEO in combination with cellulosic polymers ⁶	52	
		3.	Films containing PEOs of varying molecular weights	52	
	C.	Scope	e And Content of the Prior Art as of April 22, 2008	53	
		1.	U.S. Patent App. No. 2005/0037055 ("Yang") (Ex. 1006)	53	
VIII.	INVALIDITY OF THE '150 PATENT				
	A.	Claims 1, 3-5, 7-10, 12-14, and 15-18 are Obvious over Chen in View of Schiraldi, Claims 6 and 14 are Obvious over Chen in View of Schiraldi and Additionally in View of Chen II			
	B.		ns 1, 4-5, 8, 10, 13-14, and 17 Are Obvious Over Schiraldi ew of Verma	59	
		1.	Claims 4 and 13 are Obvious Over Schiraldi in View of Verma	64	
		2.	Claims 5, 8, 14 and 17 are Obvious Over Schiraldi in View of Verma	64	
	C.		ns 6-7, 9, 15-16, and 18 Are Obvious Over Schiraldi in of Verma and Khan	65	
		1.	Claims 6 and 15 are Obvious Over Schiraldi in View of Verma and Khan.	65	
		2.	Claims 7 and 16 are Obvious Over Schiraldi in View of Verma and Khan	65	



		3. Claims 9 and 18 are Obvious Over Schiraldi in View of Verma and Khan	65	
	D.	The Challenged Claims Would Have Been Obvious As Of April 22, 2008 Over Yang		
		1. Claims 4-9 and 13-18 Would Have Been Obvious as of April 22, 2008 Over Yang	66	
IX	CON	NCI LISION	67	



1. My name is Russell J. Mumper. I have been retained by counsel for Petitioner Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collectively – "Dr. Reddy's"). I understand that Dr. Reddy's is petitioning for *inter partes* review of U.S. Patent No. 8,017,150 (the "'150 patent"), which is owned by MonoSol RX, LLC. I further understand that Dr. Reddy's will request that the United States Patent and Trademark Office ("USPTO") cancel certain claims of the '150 patent as unpatentable. I submit this expert declaration, which addresses and supports Dr. Reddy's petition.

I. QUALIFICATIONS AND BACKGROUND

A. Education and Experience; Prior Testimony

2. Currently, I am the Vice Provost for Academic Affairs for University of Georgia at Athens, with more than 25 years of combined research, product development and teaching experience in the pharmaceutical sciences. I have been on the faculty at University of Georgia in Athens, Georgia since 2014, where I hold full Professor positions (with tenure) in both the College of Pharmacy and the College of Engineering. Prior to my employment at the University of Georgia, I was the John A. McNeill Distinguished Professor in the Division of Molecular Pharmaceutics at the University of North Carolina's ("UNC") Eshelman School of Pharmacy in Chapel Hill, NC. At UNC, I was also the founding Director of the Center for Nanotechnology in Drug Delivery and Co-Director of UNC's Institute



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

